论文部分内容阅读
用标记的HBsAg、抗-HBs、抗-HBc对482人(156名血液透析病人分别分布在HBsAg感染区和未感染区,除来自这两个不同中心的患者外,还有几个实验室中高度感染者)作了筛选研究。排除113名患者,其中来自感染区的50人出现HBsAg阳性,56人抗-HBs阳性。受高度感染的92名人员中,7人HBsAg阳性,58人抗-HBs阳性。用巴斯德研究院制备的HEVAC B抗原进行预防接种(皮下注射3次,每次间隔1个月),在第3次接种后1至3个月测定抗-HBs滴度。凡接种者在单接种疫苗后滴度
482 were labeled with HBsAg, anti-HBs, and anti-HBc (156 hemodialysis patients in the HBsAg-infected and uninfected areas, respectively, in addition to the patients from these two different centers and in several laboratories Highly infected person) made a screening study. Excluding 113 patients, 50 of them from the infected area showed positive for HBsAg and 56 were positive for anti-HBs. Among the 92 highly infected patients, 7 were HBsAg positive and 58 were anti-HBs positive. Anti-HBs titers were determined using HEVAC B antigens prepared by Pasteur Institute (3 subcutaneous injections at 1-month intervals) and 1 to 3 months after the third inoculation. All vaccinations are titrated after vaccination